Penumbra's THUNDERBOLT Stroke Device Gains CE Mark, Expanding to Europe
PEN sits 44% above its 52-week low of $221.26.
Summary
Penumbra has secured CE Mark approval for its THUNDERBOLT computer-assisted vacuum thrombectomy (CAVT) system, enabling its launch in the European market for acute ischemic stroke treatment. This follows the FDA clearance for the same device in the U.S. last week. The THUNDERBOLT system is positioned as a first-of-its-kind advancement and the only CAVT device for stroke treatment in Europe, representing a significant expansion of Penumbra's market reach for a critical product.
At the time of this announcement, PEN was trading at $319.06 on NYSE in the Life Sciences sector, with a market capitalization of approximately $12.5B. The 52-week trading range was $221.26 to $362.41. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.